Semax vs Selank: what the nootropic research shows

Semax vs Selank. These two stabilised heptapeptides are the canonical “nootropic pair” in research literature, and are often searched together — but they sit in different research strands. This guide is a research-reference comparison for Australian researchers. It makes no cognitive, anxiolytic, nootropic, or human-use claim.

Pro-cognitive versus anxiolytic

Semax (an ACTH(4-10) analogue) is framed as the pro-cognitive partner, referenced around BDNF / neurotrophic signalling. Selank (a tuftsin analogue) is framed as the anxiolytic partner, referenced around GABAergic modulation. Both use the same C-terminal Pro-Gly-Pro stabilisation strategy applied to different parent peptides — but they interrogate different neuropeptide-research strands.

What the research reports for each

Semax’s BDNF / trkB neurotrophic mechanism was reported by Dolotov and colleagues (Brain Research, 2006; Journal of Neurochemistry, 2006). Selank’s neurotrophic activity was reported by Inozemtseva and colleagues (Doklady Biological Sciences, 2008) and its GABAergic gene-expression mechanism by Volkova and colleagues (Frontiers in Pharmacology, 2016). The Semax and Selank guides cover each compound in depth.

Why they are studied together

They are the canonical “nootropic pair” — one pro-cognitive, one anxiolytic — so researchers frequently reference them side by side to contrast the neurotrophic and GABAergic strands of neuropeptide research. They are complementary research tools, not interchangeable ones.

Verification and compliance

Every batch of each compound is independently HPLC-tested by Janoshik before listing, with the certificate published in the lab-reports library. Neither is TGA-approved and neither is a therapeutic good; both are supplied strictly for in-vitro and laboratory research use only, with no cognitive, anxiolytic, or human-use claim. This comparison is a research-reference summary, not a recommendation for any use.